- June 15, 2020
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Submits Application for Additional Dosage and Administration of 5-HT3 Receptor Antagonist Aloxi® for Pediatric Patients in Japan
Taiho Pharmaceutical Co., Ltd. announced today that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare for additional dosage and administration in pediatric patients for its 5-HT3 receptor antagonist Aloxi® I.V. injection 0.75mg and Aloxi® I.V. infusion bag 0.75mg (generic name: Palonosetron Hydrochloride).
Aloxi® was developed for the prevention of nausea and vomiting resulting from administration of chemotherapeutic agents, and it has demonstrated its efficacy in delayed nausea and vomiting where available agents have hitherto provided insufficient effects. Under the license agreement signed in January 2004 with Helsinn Healthcare SA,* Taiho Pharmaceutical acquired clinical development and marketing rights in Japan, and manufacturing and marketing approval were obtained for Aloxi® I.V. injection 0.75mg in January 2010 and for Aloxi® I.V. infusion bag 0.75mg in August 2012. Aloxi® has been approved in 86 countries worldwide, as of July 2019.
Taiho Pharmaceutical goes beyond cancer treatment, striving to contribute to a better quality of life for patients.
*For more information about the Helsinn Group, please visit https://www.helsinn.com/.
Information in this news release was current as of the original release date.